Skip to main content

Table 1 Demographics and clinical characteristics of a real-world type 2 diabetes mellitus population in the US in 2015, stratified by ASCVD status

From: Impact of atherosclerotic cardiovascular disease on healthcare resource utilization and costs in patients with type 2 diabetes mellitus in a real-world setting

Patients with type 2 diabetes mellitus

Variable

Non-ASCVD

N = 659,498

(54.8%)

ASCVD

N = 543,098

(45.2%)

All patients

N = 1,202,596

(100.0%)

Age, y, mean (SD)

56.2 (11.3)

66.5 (12.3)

60.9 (12.8)

Age category, n (%)

 18–44 y

93,646 (14.2)

17,030 (3.1)

110,676 (9.2)

 45–64 y

452,819 (68.7)

254,453 (46.9)

707,272 (58.8)

  ≥ 65 y

113,033 (17.1)

271,615 (50.0)

384,648 (32.0)

Sex, n (%)

 Female

335,295 (50.8)

255,579 (47.1)

590,874 (49.1)

 Male

324,203 (49.2)

287,519 (52.9)

611,722 (50.9)

Region of US, n (%)

 North Central

143,870 (21.8)

172,345 (31.7)

316,215 (26.3)

 Northeast

123,048 (18.7)

112,886 (20.8)

235,934 (19.6)

 South

297,423 (45.1)

208,094 (38.3)

505,517 (42.0)

 West

93,867 (14.2)

48,701 (9.0)

142,568 (11.9)

 Unknown

1290 (0.2)

1072 (0.2)

2362 (0.2)

Insurance, n (%)

 Commercial

553,676 (84.0)

274,389 (50.5)

828,065 (68.9)

 Medicare

105,822 (16.1)

268,709 (49.5)

374,531 (31.1)

ASCVD diagnosisa, n (%)

 Acute coronary syndrome

–

319,931 (58.9)

319,931 (26.6)

 Angina

–

111,209 (20.5)

111,209 (9.3)

 MI

–

89,498 (16.5)

89,498 (7.4)

 Peripheral arterial disease

–

294,092 (54.2)

294,092 (24.5)

 Revascularization

–

93,365 (17.2)

93,365 (7.8)

 Stroke

–

223,736 (41.2)

223,736 (18.6)

 Transient ischemic attack

–

76,790 (14.1)

76,790 (6.4)

Hypertension, n (%)

472,299 (71.6)

478,642 (88.1)

950,941 (79.1)

Dyslipidemia, n (%)

484,175 (73.4)

450,792 (83.0)

934,967 (77.8)

Diabetes-related complicationsb, n (%)

 Cardiovascularc

23,545 (3.6)

311,388 (57.3)

334,933 (27.9)

 Cerebrovascular

0 (0.0)

118,557 (21.8)

118,557 (9.9)

 Metabolicd

79,359 (12.0)

69,721 (12.8)

149,080 (12.4)

 Nephropathy

61,975 (9.4)

121,068 (22.3)

183,043 (15.2)

 Peripheral vasculare

14,388 (2.2)

111,131 (20.5)

125,519 (10.4)

 Retinopathy

63,101 (9.6)

82,427 (15.2)

145,528 (12.1)

DCSI score, mean (SD)

0.77 (1.2)

2.7 (2.3)

1.65 (2.0)

CCI score, mean (SD)

1.7 (1.4)

3.3 (2.4)

2.4 (2.1)

  1. Note: Age, sex, region, and insurance determined as of January 1, 2015. Comorbidities were captured by any appearance during 2014–2015
  2. ASCVD Atherosclerotic cardiovascular disease, CCI Charlson Comorbidity Index, DCSI Diabetes Complications Severity Index, MI Myocardial infarction, SD standard deviation
  3. aDefined by ADA 2017 guidelines. Patients could have more than one diagnosis
  4. bComorbidities included in the Diabetes Complications Severity Index [18]
  5. cAs defined by the Diabetes Complications Severity Index [18], category includes diagnoses of atherosclerosis, other ischemic heart disease, angina, other chronic ischemic heart disease, MI, ventricular fibrillation, arrest; atrial fibrillation, arrest; other ASCVD, old MI, heart failure, atherosclerosis, severe; aortic aneurysm/dissection
  6. dCategory includes ketoacidosis, hyperosmolar, and “other coma”
  7. eCategory includes any peripheral vascular disease, not limited to “peripheral arterial disease presumed to be of atherosclerotic origin” which was part of the “ASCVD” definition
Back to article page

Clinical Diabetes and Endocrinology

ISSN: 2055-8260

Contact us